Top Health Tech Companies in Pune (52)

Strong Revenue Growth: Revenue has risen across multiple periods, including fiscal 2025 up about 9% to roughly $321 billion and mid‑single‑digit year‑over‑year increases in fiscal 2026 quarters. Disclosures also note Q4 FY2025 revenue of $83.7 billion, up 5.9% year over year.

Profitability: Adjusted operating income and EPS expanded, with FY2025 adjusted EPS up 16% to $16.00 and Q2 FY2026 GAAP EPS rising to $8.40 alongside a raised full‑year adjusted EPS outlook to about $17.70–$17.90. Management also indicated double‑digit adjusted operating income growth expected for FY2026.

Resilient & Sustainable Growth: Momentum spans FY2023–FY2026 to date, with revenue progressing from about $262 billion (FY2023) to $294 billion (FY2024) to $321 billion (FY2025) and continued gains in 2026. Portfolio refocusing and acquisitions in specialty care (e.g., Retina Consultants of America, OneOncology) are described as engines supporting ongoing expansion and margin mix.

Profitability: Profitability is highlighted as first achieved in 2023 and sustained thereafter, with the company also describing itself as cash‑flow positive. These signals point to durable unit economics and financial health.

Strong Revenue Growth: Revenue is described as growing quickly over multiple years with momentum expected to continue, while efficiency benchmarks such as the Rule of 40 have been surpassed. Together, these indicators suggest efficient, scalable growth.

Strategic Partnerships: New integrations and channels—such as embedded real‑time booking on Yelp, Healthgrades, and Google’s Gemini, along with payer partnerships—are expanding distribution and reinforcing growth. These collaborations broaden patient access points and help providers secure bookings.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Market Position & Advantage: HealthRules Payer is positioned as a leader in U.S. payer core administration, supported by repeated “Best in KLAS” mentions and ongoing Gartner recognition in core administrative processing. The company is also described as competing in a top tier with credible differentiation from a connected, modern payer platform.

Investor Backing & Capital Strength: A major ownership transition to Bain Capital and a reported multibillion-dollar transaction value indicate strong investor confidence and available capital for continued expansion. The combination with UST’s HealthProof is framed as a scale move intended to broaden the platform and accelerate growth.

Product Line Growth: The platform has expanded beyond core claims into payment integrity, care management, and member engagement through acquisitions such as The Burgess Group, Altruista Health, and Wellframe. Continued product scaling activity is highlighted through an AWS benchmark announcement intended to support very large plan volumes.

Strategic Partnerships: Partnerships with Snowflake (Select Tier), Databricks, AWS, NVIDIA Inception, and Microsoft Founders Hub are emphasized as channels to scale delivery and co-selling. These ecosystem ties support go-to-market reach and signal execution capability for a boutique services firm.

Product Line Growth: A general-availability launch of a Digital Patient Engagement platform in June 2026 and the integration of Caregence as an agentic AI platform expand the company’s healthcare solutions. This progression from services into packaged offerings indicates active product development momentum.

Market Expansion: A merger with Caregence, new U.S. presence in Texas, and multiple healthcare case studies point to expanding activity in its target vertical and geographies. Ongoing hiring posts and stated team growth further suggest an expanding footprint.

Strong Market Position & Advantage: Analyst and client recognitions position EPAM as a leader in digital engineering and AI-enabled transformation, including multiple IDC MarketScape leadership placements and a Gartner recognition for custom software development. Independent coverage likewise describes the firm as a leading provider in these segments, reinforcing a durable competitive footing.

Resilient & Sustainable Growth: Revenue continues to expand year over year in recent quarters and on a trailing-twelve-month basis, and management still guides to growth for the current year despite a tougher backdrop. The pace has moderated compared with the prior year, but the trajectory remains positive.

Innovation-Driven Growth: The company is leaning into AI-native services and is identified as a leader in AI transformation engineering alongside strengths in data modernization and software engineering. This innovation-led mix is presented as a key engine for future expansion.

Strong Market Position & Advantage: Company materials and third‑party recognition portray a fully integrated CRO/CCO with leadership status, including widespread involvement in recent FDA/EMA novel therapies and recognition as a leading pharmacovigilance provider.

Strategic Partnerships: Recent collaborations with Microsoft and KX are positioned to enable AI‑driven efficiencies across clinical and commercial operations, with reported improvements in cycle times supporting operational scalability.

Investor Backing & Capital Strength: The 2025 take‑private by investment groups (including Elliott and Veritas) provides financial sponsorship to pursue tech‑enabled growth and operational repositioning.

Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.

Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.

Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.

Strong Market Position & Advantage: Independent analyst recognition places the company in the Leaders category for payment integrity, and the narrative emphasizes deep penetration among large U.S. health plans. The materials also describe broad pre- and post-pay capabilities and repeated shortlist presence versus major peers.

Investor Backing & Capital Strength: Ownership by Veritas Capital with KKR joining as co-owner at a large valuation is presented as a durability and stability signal for the platform. The recapitalization is also framed as funding for continued product and commercial expansion.

Product Line Growth: The acquisition of Edifecs is positioned as a meaningful expansion into interoperability and value-based care capabilities, broadening the platform beyond core payment integrity. Additional launches and adjacent recognitions are cited as ongoing portfolio build-out.